A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer

Benjamin Levy, Alexander Spira, Daniel Becker, Tracey Evans, Ian Schnadig, D. Ross Camidge, Julie E. Bauman, Diana Hausman, Luke Walker, John Nemunaitis, Charles M. Rudin, Balazs Halmos, Daniel W. Bowles

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences